Mucins: A new family of epigenetic biomarkers in epithelial cancers

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 4, 2009, Pages 411-427

  Van Seuningen, Isabelle ^a   Vincent, Audrey ^a  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

Biomarker; Cancer; Epigenetics; Mucin

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY RNA; HISTONE; MICRORNA; MUCIN; MUCIN 1; MUCIN 16; MUCIN 17; MUCIN 2; MUCIN 3; MUCIN 4; MUCIN 5AC; MUCIN 5B; MUCIN 6; MUCIN 7; UNCLASSIFIED DRUG;

CANCER CELL; CANCER DIAGNOSIS; CHROMOSOME 11P; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM CANCER; DNA METHYLATION; EPIGENETICS; EPITHELIUM CELL; GENE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN MODIFICATION; REVIEW; TUMOR CLASSIFICATION;

EID: 72149127200     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050902852697     Document Type: Review

References (106)

1. Russo VEA, Martienssen RA, Riggs AD. Epigenetic mechanisms of gene regulation. New York: Cold Spring Harbor Laboratory Press, 1996
2. Tost J. Epigenetics. Norfolk: Caister Academic Press, 2008
3. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6(8):597-610
4. Chen T, Ueda Y, Dodge JE, et al. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 2003;23(16):5594-5605 (Pubitemid 36951325)
5. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007;1775(1):138-162 • This review examines how site-specific and global hypomethylation might contribute to the initiation and progression of cancer and other diseases.
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349(21):2042-2054 •• This review examines the mechanism of aberrant gene silencing in cancer and assesses the clinical potential of this knowledge for risk assessment, early diagnosis, prognostic monitoring, treatment, and the prevention of cancer.
7. Razin A. CpG methylation, chromatin structure and gene silencing-a three-way connection. Embo J 1998;17(17):4905-4908 (Pubitemid 28408457)
8. Cervoni N, Szyf M. Demethylase activity is directed by histone acetylation. J Biol Chem 2001;276(44):40778-40787 (Pubitemid 37373223)
9. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. Embo J 2004;23(1):138-149 (Pubitemid 38165754)
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-297 (Pubitemid 38167318)
11. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5(7):522-531 •• This review revisits the history of miRNAs and summarizes recent findings in miRNA biogenesis, translational repression and biological function.
12. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007;43(10):1529-1544 •• This review presents genome-wide and quantitative, high- resolution methods for methylation analysis that are used in the laboratory and clinic, and discusses their potential for use in a clinical setting.
13. Shames DS, Minna JD, Gazdar AF. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 2007;251(2):187-198 (Pubitemid 46669792)
14. Teodoridis JM, Strathdee G, Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat 2004;7(4-5):267-278 (Pubitemid 39469099)
15. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60(21):5954-5958 (Pubitemid 30839621)
16. Worm J, Guldberg P. DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J Oral Pathol Med 2002;31(8):443-449 (Pubitemid 35045028)
17. Strathdee G, Brown R. Epigenetic cancer therapies: DNA methyltransferase inhibitors. Expert Opin Investig Drugs 2002;11(6):747-754 (Pubitemid 34618808)
18. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5(1):37-50
19. Liang JJ, Kimchi ET, Staveley-O'Carroll KF, Tan D. Diagnostic and prognostic biomarkers in pancreatic carcinoma. Int J Clin Exp Pathol 2009;2(1):1-10
20. Van Seuningen I, Pigny P, Perrais M, et al. Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer? Front Biosci 2001;6:D1216-34
21. Mall AS. Analysis of mucins: role in laboratory diagnosis. J Clin Pathol 2008;61(9):1018-1024
22. Leteurtre E, Piessen G, Aubert S, et al. Mucins as diagnostic and/or prognostic factors in epithelial cancers. In: Van Seuningen I, editor, The epithelial mucins: structure/function Roles in cancer and inflammatory diseases. Kerala: Research Signpost; 2008. p. 273-294 •• This chapter reviews studies performed to evaluate mucins as biomarkers and discusses their potential as prognostic and/or diagnostic markers in epithelial cancers.
23. Pigny P, Guyonnet-Duperat V, Hill AS, et al. Human mucin genes assigned to 11p15.5: identification and organization of a cluster of genes. Genomics 1996;38(3):340-352 (Pubitemid 27030123)
24. de Bustros A, Nelkin BD, Silverman A, et al. The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 1988;85(15):5693-5697
25. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4(1):45-60 (Pubitemid 38082153)
26. Jonckheere N, Van Seuningen I. The ever growing family of membrane-bound mucins. In: Van Seuningen I, editor, The epithelial mucins: structure/function Roles in cancer and inflammatory diseases. Kerala: Research Signpost; 2008. p. 17-38
27. Yonezawa S, Goto M, Yamada N, et al. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 2008;8(16):3329-3341
28. Gicquel C, Rossignol S, Cabrol S, et al. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. Nat Genet 2005;37(9):1003-1007 (Pubitemid 43086160)
29. Schonherr N, Meyer E, Roos A, etal. The centromeric 11p15 imprinting centre is also involved in Silver-Russell syndrome. J Med Genet 2007;44(1):59-63 (Pubitemid 46142840)
30. Weksberg R, Smith AC, Squire J, Sadowski P. Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet 2003;12 Spec No 1:R61-8 (Pubitemid 36442955)
31. Craig JM, Bickmore WA. The distribution of CpG islands in mammalian chromosomes. Nat Genet 1994;7(3):376-382 (Pubitemid 24204413)
32. Nakano S, Murakami K, Meguro M, et al. Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers. Cancer Sci 2006;97(11):1147-1154 (Pubitemid 44430639)
33. Sato N, Matsubayashi H, Abe T, et al. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005;11(13):4681-4688 (Pubitemid 41557185)
34. Schwienbacher C, Gramantieri L, Scelfo R, et al. Gain of imprinting at chromosome 11p15: a pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci USA 2000;97(10):5445-5449 (Pubitemid 30313738)
35. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002;295(5560):1726-1729 •• This paper was the first study to assess the biological role of a secreted mucin by using genetically deficient mice and to propose a role of tumour suppressor gene for Muc2.
36. Hanski C, Riede E, Gratchev A, et al. MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. Lab Invest 1997;77(6):685-695 •• This paper was the first to assess the role of methylation in the silencing of a mucin gene in cancer.
37. Gratchev A, Siedow A, Bumke-Vogt C, et al. Regulation of the intestinal mucin MUC2 gene expression invivo: evidence for the role of promoter methylation. Cancer Lett 2001;168(1):71-80 (Pubitemid 32463915)
38. Siedow A, Szyf M, Gratchev A, et al. De novo expression of the Muc2 gene in pancreas carcinoma cells is triggered by promoter demethylation. Tumour Biol 2002;23(1):54-60 (Pubitemid 34225022)
39. Mesquita P, Peixoto AJ, Seruca R, et al. Role of site-specific promoter hypomethylation in aberrant MUC2 mucin expression in mucinous gastric carcinomas. Cancer Lett 2003b;189(2):129-136 (Pubitemid 35469124)
40. Hamada T, Goto M, Tsutsumida H, et al. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing. Cancer Lett 2005;227(2):175-184 (Pubitemid 41169931)
41. Yamada N, Hamada T, Goto M, et al. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer 2006;119(8):1850-1857 (Pubitemid 44356842)
42. Perrais M, Pigny P, Buisine MP, et al. Aberrant expression of human mucin gene MUC5B in gastric carcinoma and cancer cells. Identification and regulation of a distal promoter. J Biol Chem 2001;276(18):15386-15396 (Pubitemid 37373431)
43. Ho JJ, Han SW, Pan PL, etal. Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells. Int J Oncol 2003;22(2):273-279
44. Vincent A, Perrais M, Desseyn JL, et al. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007;26(45):6566-6576 •• This paper assesses the epigenetic regulation of the four genes of the 11p15 MUC cluster, which encode MUC2, MUC5AC, MUC5B and MUC6 secreted mucins.
45. Augenlicht L, Shi L, Mariadason J, et al. Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. Oncogene 2003;22(32):4983-4992 (Pubitemid 37026397)
46. Mayo C, Lloreta J, Real FX, Mayol X. Invitro differentiation of HT-29 M6 mucus-secreting colon cancer cells involves a trychostatin A and p27(KIP1)-inducible transcriptional program of gene expression. J Cell Physiol 2007;212(1):42-50 (Pubitemid 46867585)
47. Smiraglia DJ, Rush LJ, Fruhwald MC, et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001;10(13):1413-1419 (Pubitemid 32640670)
48. Vincent A, Ducourouble MP, Van Seuningen I. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. FASEB J 2008;22(8):3035-3045
49. Jonckheere N, Perrais M, Mariette C, et al. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene 2004;23(34):5729-5738 (Pubitemid 39093018)
50. Singh AP, Chauhan SC, Bafna S, et al. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate 2006;66(4):421-429 (Pubitemid 43348735)
51. Perrais M, Pigny P, Ducourouble MP, et al. Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. J Biol Chem 2001;276(33):30923-30933 (Pubitemid 37384954)
52. Fauquette V, Aubert S, Groux-Degroote S, et al. Transcription factor AP-2alpha represses both the mucin MUC4 expression and pancreatic cancer cell proliferation. Carcinogenesis 2007;28(11):2305-2312 (Pubitemid 350119564)
53. Yamada N, Nishida Y, Tsutsumida H, et al. Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. Br J Cancer 2009;100(2):344-351
54. Zrihan-Licht S, Weiss M, Keydar I, Wreschner DH. DNA methylation status of the MUC1 gene coding for a breast-cancer-associated protein. Int J Cancer 1995;62(3):245-251
55. Yamada N, Nishida Y, Tsutsumida H, et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res 2008;68(8):2708-2716 (Pubitemid 351556268)
56. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007;2(9):2265-2275 • A detailed protocol for quantitative DNA methylation analysis using the pyrosequencing technology.
57. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8(4):286-298 •• This excellent review provides a broad picture of how the current knowledge of epigenetic defects in cancer cells is beginning to be extended following the recent advent of genome-scale technologies to map DNA methylation and histone modifications.
58. Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development 2007;134(22):3959-3965 (Pubitemid 350269413)
59. Omura N, Li CP, Li A, etal. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 2008;7(7):1146-1156
60. Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 2006;38(2):149-153 (Pubitemid 43177227)
61. Taylor KH, Kramer RS, Davis JW, et al. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res 2007;67(18):8511-8518 (Pubitemid 47437425)
62. Massie CE, Mills IG. ChIPping away at gene regulation. EMBO Rep 2008;9(4):337-343
63. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857-866 • This review focuses on the causes of the widespread differential expression of miRNA genes in malignant compared with normal cells and how miRNA-expression profiling of human tumours has identified signatures associated with diagnosis, staging, progression, prognosis and response to treatment.
64. Gonzalez S, Pisano DG, Serrano M. Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle 2008;7(16):2601-2608
65. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007;13(1):151-159 (Pubitemid 46026189)
66. Wang Y, Liang Y, Lu Q. MicroRNA epigenetic alterations: predicting biomarkers and therapeutic targets in human diseases. Clin Genet 2008;74(4):307-315
67. Lee YS, Dutta A. MicroRNAs in Cancer. Annu Rev Pathol 2009;4:199-227
68. Zhang B, Farwell MA. microRNAs: a new emerging class of players for disease diagnostics and gene therapy. J Cell Mol Med 2008;12(1):3-21
69. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27(15):2128-2136
70. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297(17):1901-1908 (Pubitemid 46707844)
71. Lee EJ, Gusev Y, Jiang J, etal. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120(5):1046-1054 (Pubitemid 46214304)
72. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26(30):4442-4452 (Pubitemid 47014466)
73. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007;25(5):387-392 (Pubitemid 47362758)
74. Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008;135(2):255-60; discussion 60
75. Volinia S, Calin GA, Liu CG, etal. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103(7):2257-2261
76. Mascaux C, Laes JF, Anthoine G, et al. Evolution of microRNAs expression during human bronchial squamous carcinogenesis. Eur Respir J 2009;33(2):352-359
77. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008;105(36):13556-13561
78. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26(4):462-469
79. Love TM, Moffett HF, Novina CD. Not miR-ly small RNAs: big potential for microRNAs in therapy. J Allergy Clin Immunol 2008;121(2):309-319 (Pubitemid 351215186)
80. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105(30):10513-10518
81. Available from: http://microrna.sanger.ac.uk/targets
82. Available from: http://www.microrna.org
83. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34(Database issue):D140-4
84. John B, Enright AJ, Aravin A, et al. Human MicroRNA targets. PLoS Biol 2004;2(11):e363
85. Ramasamy S, Duraisamy S, Barbashov S, et al. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 2007;27(6):992-1004 (Pubitemid 47488189)
86. Yu W, Gius D, Onyango P, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008;451(7175):202-206
87. Lapidot M, Pilpel Y. Genome-wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms. EMBO Rep 2006;7(12):1216-1222 (Pubitemid 44835088)
88. He Y, Vogelstein B, Velculescu VE, et al. The antisense transcriptomes of human cells. Science 2008;322(5909):1855-1857
89. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4(9):707-717 (Pubitemid 39215069)
90. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006;66(2):1208-1217 (Pubitemid 43165992)
91. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007;3(9):1709-1723 (Pubitemid 47510263)
92. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3(4):253-266 (Pubitemid 37328861)
93. Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7(9):2727-2730 (Pubitemid 32911377)
94. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92(22):1805-1811 (Pubitemid 30945195)
95. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4(12):988-993 (Pubitemid 39626222)
96. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006;3(12):e486 (Pubitemid 46028510)
97. Mizoshita T, Tsukamoto T, Inada KI, et al. Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon. Histol Histopathol 2007;22(3):251-260 (Pubitemid 46117111)
98. Copin MC, Buisine MP, Devisme L, et al. Normal respiratory mucosa, precursor lesions and lung carcinomas: differential expression of human mucin genes. Front Biosci 2001;6:D1264-75
99. Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005;18(10):1295-1304 (Pubitemid 41348648)
100. Swartz MJ, Batra SK, Varshney GC, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 2002;117(5):791-796 (Pubitemid 34457016)
101. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23(1-2):77-99 (Pubitemid 38221597)
102. Chaturvedi P, Singh AP, Moniaux N, et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 2007;5(4):309-320 (Pubitemid 46706993)
103. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006;94(2):179-183 (Pubitemid 43151531)
104. Li Y, Liu D, Chen D, etal. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003;22(38):6107-6110
105. Piacentini P, Donadelli M, Costanzo C, et al. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006;448(6):797-804 (Pubitemid 43824437)
106. Van Seuningen I, Perrais M, Pigny P, et al. Sequence of the 5′-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells. Biochem J 2000;348(Pt 3):675-686 (Pubitemid 30410259)